141 related articles for article (PubMed ID: 12028032)
1. Low concentrations of STI571 in the cerebrospinal fluid: a case report.
Petzer AL; Gunsilius E; Hayes M; Stockhammer G; Duba HC; Schneller F; Grünewald K; Poewe W; Gastl G
Br J Haematol; 2002 Jun; 117(3):623-5. PubMed ID: 12028032
[TBL] [Abstract][Full Text] [Related]
2. CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid.
Bornhauser M; Jenke A; Freiberg-Richter J; Radke J; Schuler US; Mohr B; Ehninger G; Schleyer E
Ann Hematol; 2004 Jun; 83(6):401-2. PubMed ID: 14673623
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of extramedullary blast crisis of chronic myelogenous leukemia with imatinib mesylate (STI571).
Naito K; Mori T; Miyazaki K; Tsukada Y; Ikeda Y; Okamoto S
Intern Med; 2003 Aug; 42(8):740-2. PubMed ID: 12924504
[TBL] [Abstract][Full Text] [Related]
4. Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid.
Takayama N; Sato N; O'Brien SG; Ikeda Y; Okamoto S
Br J Haematol; 2002 Oct; 119(1):106-8. PubMed ID: 12358909
[TBL] [Abstract][Full Text] [Related]
5. [STI571: a new dimension in the treatment of chronic myeloid leukemia].
Somers JA; Shamelian SO; Löwenberg B; Ossenkoppele GJ; Cornelissen JJ
Ned Tijdschr Geneeskd; 2002 Jan; 146(3):128-32. PubMed ID: 11826673
[TBL] [Abstract][Full Text] [Related]
6. Extramedullary blast crisis derived from 2 different clones in the central nervous system and neck during complete cytogenetic remission of chronic myelogenous leukemia treated with imatinib mesylate.
Matsuda M; Morita Y; Shimada T; Miyatake J; Hirase C; Tanaka M; Tatsumi Y; Maeda Y; Kanamaru A
Int J Hematol; 2005 May; 81(4):307-9. PubMed ID: 15914360
[TBL] [Abstract][Full Text] [Related]
7. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
[TBL] [Abstract][Full Text] [Related]
8. [Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor].
Nakajima M; Toga W
Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):482-90. PubMed ID: 14639002
[TBL] [Abstract][Full Text] [Related]
9. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
Sureda A; Carrasco M; de Miguel M; Martínez JA; Conde E; Sanz MA; Díaz-Mediavilla J; Sierra J
Haematologica; 2003 Nov; 88(11):1213-20. PubMed ID: 14607749
[TBL] [Abstract][Full Text] [Related]
10. Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy.
Bujassoum S; Rifkind J; Lipton JH
Leuk Lymphoma; 2004 Feb; 45(2):401-3. PubMed ID: 15101732
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
[TBL] [Abstract][Full Text] [Related]
12. Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials.
Silver RT; Cortes J; Waltzman R; Mone M; Kantarjian H
Haematologica; 2009 May; 94(5):743-4. PubMed ID: 19407320
[No Abstract] [Full Text] [Related]
13. Imatinib and chronic myeloid leukemia: validating the promise of molecularly targeted therapy.
Druker BJ
Eur J Cancer; 2002 Sep; 38 Suppl 5():S70-6. PubMed ID: 12528776
[TBL] [Abstract][Full Text] [Related]
14. Clinical and genetic studies of ETV6/ABL1-positive chronic myeloid leukaemia in blast crisis treated with imatinib mesylate.
Barbouti A; Ahlgren T; Johansson B; Höglund M; Lassen C; Turesson I; Mitelman F; Fioretos T
Br J Haematol; 2003 Jul; 122(1):85-93. PubMed ID: 12823349
[TBL] [Abstract][Full Text] [Related]
15. Sensitivity to the abl inhibitor STI571 in fresh leukaemic cells obtained from chronic myelogenous leukaemia patients in different stages of disease.
Gambacorti-Passerini C; Barni R; Marchesi E; Verga M; Rossi F; Rossi F; Pioltelli P; Pogliani E; Corneo GM
Br J Haematol; 2001 Mar; 112(4):972-4. PubMed ID: 11298594
[TBL] [Abstract][Full Text] [Related]
16. STI571: a magic bullet?
Verweij J; Judson I; van Oosterom A
Eur J Cancer; 2001 Oct; 37(15):1816-9. PubMed ID: 11576833
[No Abstract] [Full Text] [Related]
17. Isolated central nervous system blast crisis in chronic myeloid leukemia.
Rajappa S; Uppin SG; Raghunadharao D; Rao IS; Surath A
Hematol Oncol; 2004 Dec; 22(4):179-81. PubMed ID: 15995975
[TBL] [Abstract][Full Text] [Related]
18. [Bcr-Abl inhibition as molecular therapy approach in chronic myeloid leukemia].
Buchdunger E
Med Klin (Munich); 2002 Jan; 97 Suppl 1():2-6. PubMed ID: 11831067
[TBL] [Abstract][Full Text] [Related]
19. Chronic myelogenous leukemia in chronic phase.
Kurzrock R; Kantarjian H; Talpaz M
Curr Treat Options Oncol; 2001 Jun; 2(3):245-52. PubMed ID: 12057124
[TBL] [Abstract][Full Text] [Related]
20. Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis.
Beham-Schmid C; Apfelbeck U; Sill H; Tsybrovsky O; Höfler G; Haas OA; Linkesch W
Blood; 2002 Jan; 99(1):381-3. PubMed ID: 11756197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]